About UQUIFA Group
UQUIFA Group is a company based in Barcelona (Spain) founded in 1936 was acquired by Vivimed Labs in December 2011. UQUIFA Group has raised $42.5 million across 2 funding rounds from investors including Orbimed, Vivimed Labs and Asian Credit Fund. The company has 28 employees as of March 23, 2024. UQUIFA Group has completed 1 acquisition, including Soneas. UQUIFA Group offers products and services including API Portfolio and CDMO Services. UQUIFA Group operates in a competitive market with competitors including Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others.
- Headquarter Barcelona, Spain
- Employees 28 as on 23 Mar, 2024
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Uquifa India Private Limited
- Date of Incorporation 12 Jul, 2017
- Jurisdiction Hayathnagar, Telangana, India
-
Annual Revenue
$1.34 M (USD)-15.2as on Mar 31, 2023
-
Net Profit
$14.73 K (USD)114.76as on Mar 31, 2023
-
EBITDA
$43.03 K (USD)191.48as on Mar 31, 2023
-
Total Equity Funding
$42.5 M (USD)
in 2 rounds
-
Latest Funding Round
$35.75 M (USD), Debt – Conventional
Mar 10, 2025
-
Investors
Orbimed
& 2 more
-
Employee Count
28
as on Mar 23, 2024
- Investments & Acquisitions
-
Acquired by
Vivimed Labs
(Dec 01, 2011)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of UQUIFA Group
UQUIFA Group offers a comprehensive portfolio of products and services, including API Portfolio and CDMO Services.
Collection of active pharmaceutical ingredients for global use.
Contract development and manufacturing for pharmaceutical clients.
People of UQUIFA Group
Unlock access to complete
Funding Insights of UQUIFA Group
UQUIFA Group has successfully raised a total of $42.5M across 2 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $35.75 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in UQUIFA Group
UQUIFA Group has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Vivimed Labs and Asian Credit Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Micro credit services are provided to underserved communities in Kazakhstan.
|
Locked | Locked | Locked | |
|
Active pharmaceutical ingredients, formulations, and specialty chemicals are manufactured.
|
Locked | Locked | Locked |
Investor details for UQUIFA Group
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by UQUIFA Group
UQUIFA Group has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Soneas.
Investment portfolio details for UQUIFA Group
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
CDMO with expertise in olefine metathesis reactions
|
Locked | Locked | 1996 | Locked |
Complete acquisition details for UQUIFA Group
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - UQUIFA Group
Detailed financials for UQUIFA Group
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Uquifa Group Comparisons
Peer comparison for UQUIFA Group
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of UQUIFA Group
UQUIFA Group operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical and biotechnology company
|
|
| Locked | Locked | Locked |
Contract development, manufacturing, and analytical services for APIs are offered.
|
|
| Locked | Locked | Locked |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| Locked | Locked | Locked |
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
|
|
| Locked | Locked | Locked |
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
|
|
| Locked | Locked | Locked |
APIs are manufactured and custom synthesis services are provided.
|
Detailed competitors of UQUIFA Group
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Uquifa Group
Complete news archive for UQUIFA Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about UQUIFA Group
UQUIFA Group was founded in 1936 and raised its 1st funding round 81 years after it was founded.
UQUIFA Group is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Saurabh Gurnurkar is the current CEO of UQUIFA Group.
UQUIFA Group is a funded company, having raised a total of $42.5M across 2 funding rounds to date.
As of Mar 23, 2024, the latest employee count at UQUIFA Group is 28.
Annual revenue of UQUIFA Group is $1.34M as on Mar 31, 2023.
UQUIFA Group was established in 1936 in Barcelona, Spain, as a CDMO in the pharmaceutical and chemical sectors. APIs and intermediates are produced to support customer programs for new chemical entities, spanning pre-clinical development through to commercial-scale manufacturing. Capabilities encompass hydrogenation, chlorination, and micronization processes, with operations centered in Europe.
UQUIFA Group's top competitors include Laurus Labs, Symbiotec and Sterling Pharma Solutions.
UQUIFA Group offers API Portfolio and CDMO Services.
UQUIFA Group has made 1 acquisition, including Soneas.
UQUIFA Group has 3 investors. Key investors include Orbimed, Vivimed Labs, and Asian Credit Fund.